Please login to the form below

Not currently logged in
Email:
Password:

Immatics

This page shows the latest Immatics news and features for those working in and with pharma, biotech and healthcare.

Roche pays $1bn-plus for stake in genomics specialist

Roche pays $1bn-plus for stake in genomics specialist

In 2013 Roche licensed a series of early-stage cancer immunotherapy programmes from German company Immatics in a deal valued at more than $1bn, and promised up to $422.5m to

Latest news

More from news
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2017 Deal Watch January 2017

    was Amgen with the purchase of Immatics' next-generation, T-cell engaging bispecific immunotherapies. ... Immatics. Amgen. Licence /  joint development. Next-generation, T-cell engaging bispecific immuno-therapies .

  • Deal Watch table for November 2013 Deal Watch table for November 2013

    hyperactivity disorder, pain, urology and allergy. 1, 600. immatics / Roche.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

  • Peter Chambre joins cancer vaccine biotech Immatics Peter Chambre joins cancer vaccine biotech Immatics

    Paul Higham, CEO of Immatics, said: “I am delighted to welcome Peter as our new chairman. ... He said: “Immatics' vaccines, based on the company's highly rational approach to cancer vaccine discovery, have already demonstrated very promising results

More from appointments
Approximately 1 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics